摘要
目的:探讨紫杉醇联合奈达铂或顺铂治疗晚期食管癌的临床疗效及不良反应。方法:回顾性分析94例经病理确诊的Ⅳ期食管癌,随机分为紫杉醇联合奈达铂组(TN组)与紫杉醇联合顺铂组(TP组),TN组42例,紫杉醇135mg/m2,静脉滴入,d1;奈达铂25mg/m2,静脉滴入,d1～d3,21d为1个周期。TP组52例,紫杉醇135mg/m2,静脉滴入,d1;顺铂25mg/m2,静脉滴入,d1～d3,21d为1个周期。结果:TN组和TP组有效率分别为53.3%和55.4%(χ2=0.11,P=0.743),疾病控制率分别83.6%和86.2%(χ2=0.2,P=0.660),1年生存率分别为33.3%和36.5%(χ2=0.1,P=0.750);不良反应方面:TP组比TN组Ⅰ～Ⅱ恶心、呕吐(67.3%vs28.6%,χ2=13.9,P=0.000),Ⅲ～Ⅳ恶心、呕吐(15.4%vs2.4%,χ2=4.54,P=0.033)及外周神经毒性(46.2%vs21.4%,χ2=6.325,P=0.013)发生率更高。结论:紫杉醇联合奈达铂是治疗晚期食管癌的有效方案,可取得与紫杉醇联合顺铂相似的有效率与生存,在不良反应方面具有一定的优势。
OBJECTIVE：To evaluate the efficacy and toxicity of paclitaxel plus nedaplatin（TN）and paclitaxel plus cisplatin（TP）combinations in the treatment of advanced esophageal carcinoma.METHODS：The randomization-cotrolled clinical study was conducted.Forty-two patients in the TN group received paclitaxel 135 mg/m2（d1）and nedaplatin 25 mg/m2（d1-d3）,52 patients in the TP group received paclitaxel 135 mg/m2（d1）and cisplatin 25 mg/m2（d1-d3）,and both regimens were repeated every 3 weeks.RESULTS：The overall response rates were 53.3 % and 55.4 %（χ2=0.11,P=0.743）,and the disease control rates were 83.6% and 86.2%（χ2=0.2,P=0.660）in the TN and TP groups respectively;1-year survival rate was 33.3% vs 36.5%（χ2=0.1,P=0.750）respectively.More patients in the TP group suffered from Ⅰ-Ⅱ degree nausea and vomiting（67.3% vs 28.6%,χ2=13.9,P=0.000）,Ⅲ-Ⅳ degree nausea and vomiting（15.4% vs 2.4%,χ2=4.54,P=0.033）and peripheral neurotoxicity（46.2% vs 21.4%,χ2=6.325,P=0.013）.CONCLUSION：Paclitaxel plus nedaplatin is an effective treatment regiment for esophageal carcinoma patients.when compared with the regiment of cisplatin,and the response rate and survival are similar,however,the TN group shows some superiority as regards the treatment side effect.
出处
《中华肿瘤防治杂志》
CAS
2010年第9期693-695,共3页
Chinese Journal of Cancer Prevention and Treatment
关键词
食管肿瘤/药物疗法
抗肿瘤联合化疗方案
预后
esophageal neoplasms/drug therapy
antineoplastic combined chemotherapy protocols
prognosis
作者简介
喻杰，湖南长沙人，硕士，主要从事胸部肿瘤诊治的研究工作。Tel：86-51497323677 E—mail：yujie162@126．com
【通讯作者简介】汪步海，男，浙江桐庐人，博士，副主任医师硕士生导师，主要从事食管癌诊断和治疗的研究工作。Tel：86-514—87977690 E—mail：wbhself@sina．com
